Last reviewed · How we verify
Caffeine Pill
Caffeine blocks adenosine receptors in the central nervous system, reducing drowsiness and increasing alertness and mental focus.
Caffeine blocks adenosine receptors in the central nervous system, reducing drowsiness and increasing alertness and mental focus. Used for Fatigue and drowsiness, Cognitive enhancement and mental alertness.
At a glance
| Generic name | Caffeine Pill |
|---|---|
| Sponsor | Rothman Institute Orthopaedics |
| Drug class | Adenosine receptor antagonist |
| Target | Adenosine receptors (A1, A2A) |
| Modality | Small molecule |
| Therapeutic area | Neurology / Stimulant |
| Phase | Phase 3 |
Mechanism of action
Caffeine is a non-selective adenosine receptor antagonist that crosses the blood-brain barrier and competitively inhibits adenosine binding at A1 and A2A receptors. By blocking adenosine—a neurotransmitter that promotes sleep and relaxation—caffeine increases neuronal firing and the release of excitatory neurotransmitters like dopamine and norepinephrine, resulting in increased wakefulness, improved concentration, and enhanced cognitive performance.
Approved indications
- Fatigue and drowsiness
- Cognitive enhancement and mental alertness
Common side effects
- Jitteriness / tremor
- Insomnia
- Anxiety
- Headache
- Tachycardia
Key clinical trials
- Effects of Caffeine Ingestion on Morning Cognitive and Muscle Repeated Sprint Performance in Males (EARLY_PHASE1)
- Effects of Caffeine Ingestion on Morning Cognitive and 4-km Time Trial Performance in Males (PHASE1, PHASE2)
- Effects of Caffeine Ingestion on Morning Cognitive and Muscle Strength Measures in Males (PHASE4)
- Exploring Sympathetic Nervous System Function in Individuals With Down Syndrome (PHASE3)
- The Effects of Caffeine on Exercise Physiology and Time-trial Performance in a Hot Environment (NA)
- The Repeatability of the Effect of Caffeine Supplementation on Submaximal Physiological Responses and Cycling Time Trial Performance (NA)
- Oral Caffeine Use for Pain Management in AIS Patients After Spinal Fusion (PHASE4)
- An Electronic Clinical Decision Support Tool to Reduce Low-value Antipsychotic Prescriptions (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Caffeine Pill CI brief — competitive landscape report
- Caffeine Pill updates RSS · CI watch RSS
- Rothman Institute Orthopaedics portfolio CI